- WeedMD (WMD) is collaborating with CannTx Life Sciences to release high-THC craft strains Rockstar Tuna and Royal Goddess for Starseed patients
- The ‘Limited Edition’ release of these high-THC whole flower products will be available starting in late May 2021
- WeedMD Inc. is the publicly traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets
- WeedMD Inc. (WMD) is down 1.82 per cent and is trading at C$0.27 at 11:53 am ET
WeedMD Inc. (WMD), has entered into an exclusive licensing and supply agreement with Ontario craft cannabis producer CannTx Life Sciences Inc.
Together, the companies will release celebrated cultivars “Rockstar Tuna” and “Royal Goddess” – re-labelled “Crown” – for its Starseed Medicinal patients.
The ‘Limited Edition’ release of these high-THC whole flower products will be available starting in late May 2021.
CannTx is a highly regarded licensed producer that specializes in small-batch, hand-crafted cultivation utilizing tissue cultured donor-stock, as well as full-spectrum, solventless concentrates such as ice hash and rosin.
Its adult-use brand Royal City Cannabis Co.’s celebrated cultivars and pressed ice hash products are sold in the “Craft Cultivator” category in Ontario’s retail markets.
“This unique partnership is a natural fit for both WeedMD and CannTx, bringing together complementary renowned cultivars, with distinctive terpene profiles, that are hand-crafted for our medical patients by this University of Guelph-affiliated micro-propagator,” said Joseph Mele, SVP, Commercial Sales and Marketing, WeedMD.
“Together, we’re proud to be leading the wave of change that is bringing greater choice, quality, and value in cannabis products for Canadians,” added Mele.
“We pride ourselves on hand-crafting artisanal, small-batch products that are appreciated by discerning patients, and we’re thrilled to be collaborating with a producer that shares our brand ethos,” said Buck Young, Director and Co-Founder of CannTx.
“WeedMD is a long-time, highly valued partner that has built a strong distribution network and reputation for excellence and we’re looking forward to continuing to bring more innovative products to market together,” added Young.
WeedMD and CannTx have had a long-standing commercial relationship.
In July 2020, the parties announced an agreement to enhance the Weed MD’s genetics bank with new cultivars and to preserve the lifecycle of elite proprietary strains such as Pedro’s Sweet Sativa using tissue culture technology.
This has allowed WeedMD and its brands to consistently and perpetually clone, grow and produce the same great products on which they’ve built a solid reputation.
In addition to expanding WeedMD’s genetics bank and cultivars’ lifecycle with its rejuvenation techniques, CannTx’s platform also banks genetic material for secure storage and plant asset preservation.
WeedMD Inc. is the publicly traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets.
WeedMD Inc. (WMD) is down 1.82 per cent and is trading at C$0.27 at 11:53 am ET.
